

# Ontario Public Drug Programs

Drug Submission Status  
Updated: September 19, 2014

## Complete Streamlined Multiple-Source Submissions for Off-Formulary Interchangeability

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via an OPDP Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Apotex Inc.	Apo-Bosentan	Tracleer	bosentan	62.5mg	FC tablet	02399202
Apotex Inc.	Apo-Bosentan	Tracleer	bosentan	125mg	FC tablet	02399210
Marcan Pharmaceuticals Inc.	Mar-Cetirizine	Reactine	cetirizine HCl	10mg	FC tablet	02427133
Marcan Pharmaceuticals Inc.	Mar-Cetirizine	Reactine	cetirizine HCl	20mg	FC tablet	02427141
Omega Laboratories Ltd.	Zoledronic Acid for Injection Concentrate	Zometa Concentrate	zoledronic acid monohydrate	4mg/5mL	IV solution	02413701

<b>Manufacturer</b>	<b>Product</b>	<b>Reference Product</b>	<b>Generic Name</b>	<b>Strength</b>	<b>Dosage Form</b>	<b>DIN</b>
Pharmascience Inc.	Pms-Entecavir	Baraclude	entecavir	0.5mg	FC tablet	02430576
Teva Canada Limited	Linezolid Injection	Zyvoxam	linezolid	2mg/mL	IV solution	02402637